Non-Statin Lipid Lowering Agents

This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages.

Drug Classes Covered:

• Bempedoic Acid
• Inclisiran
• PCSK9 Inhibitors (Evolocumab, Alirocumab)
• Ezetimibe
• Bile Acid Sequestrants
• Niacin
• Fibrates
• Omega-3 Fatty Acids (EPA)

Each agent shows unique attributes in lipid lowering, cardiovascular impact, and side effect profiles. Notably:

• PCSK9 inhibitors and Inclisiran provide substantial LDL-C reduction.
• Fibrates and Omega-3 fatty acids show greater triglyceride reduction benefits, useful in hypertriglyceridemia.
• Bempedoic Acid and Ezetimibe offer alternatives to statins, especially for those with statin-associated muscle symptoms.

Produced by: Dr. Natalie Marreromed
Reviewed by: Dr. Patrick Zakka

CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!